Banco Bilbao Vizcaya Argentaria, S.A. vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Banco Bilbao Vizcaya Argentaria, S.A. on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson is widest.

On the headline numbers, Banco Bilbao Vizcaya Argentaria, S.A. reports annual revenue of ~$41.7B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $139.7B and $643.9B. Banco Bilbao Vizcaya Argentaria, S.A. is headquartered in Spain and Johnson & Johnson in United States, and those different home markets shape how each company competes.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA is a Spanish banking group that earns more abroad than at home. It is Spain's second-largest bank, but Mexico produced ~$5.95B (EUR5.264B) of its ~$11.9B (EUR10.511B) net attributable profit in 2025, with Turkey, Colombia, Peru, Argentina, Uruguay and a corporate and investment banking arm making up the rest. The group employed 127,174 people at the end of 2025 and served 81.2 million active customers.

Johnson & Johnson: Johnson & Johnson is one of the largest healthcare companies in the world by revenue and market value. Once known for Band-Aid, Tylenol, and baby powder, it moved those consumer brands into Kenvue in 2023 and now reports two segments: Innovative Medicine and MedTech. In 2025 it generated $94.2 billion in sales with about 140,800 employees, and in 2026 it is aiming for more than $100 billion in revenue during its 140th year.

Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson.

Banco Bilbao Vizcaya Argentaria, S.A. business model: BBVA runs a universal banking model built on local subsidiaries that fund themselves with local deposits, so a shock in one country does not drain the parent. Customer deposits reached ~$568B (EUR502.5B) at the end of 2025 against ~$534B (EUR472.7B) of gross loans, and net interest income of ~$29.7B (EUR26.280B) provided about 71 percent of gross income. Fees from payments, cards, asset management and insurance added ~$9.28B (EUR8.215B) and net trading income ~$3B (EUR2.656B). Distribution is mostly digital: 81.2 million active customers were served through 5,642 branches and 31,015 ATMs, and the efficiency ratio of 38.8 percent is one of the lowest among large European banks.

Johnson & Johnson business model: J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal. Margins depend on patent protection, so growth relies on launching new drugs as older ones such as STELARA face biosimilars. MedTech (about 36%, $33.8 billion) sells surgical tools, wound closure, orthopaedic implants, electrophysiology catheters and mapping systems, Abiomed heart pumps, Shockwave lithotripsy devices, and contact lenses to hospitals and surgery centers, with much of the revenue coming from recurring disposables and implants.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Banco Bilbao Vizcaya Argentaria, S.A. stack up against those of Johnson & Johnson.

Banco Bilbao Vizcaya Argentaria, S.A. competitive advantage: BBVA's first advantage is scale in Mexico, where BBVA Mexico is the largest bank in the country and produced ~$5.95B (EUR5.264B) of net attributable profit in 2025, close to half the group total. The second is cost: operating expenses grew 1.0 percent in euros in 2025 while gross income grew 4.1 percent, holding the efficiency ratio at 38.8 percent with a branch network trimmed to 5,642 offices. Group ROTE of 19.3 percent is a level BBVA describes as leading among large European banks.

Johnson & Johnson competitive advantage: J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time. That diversification lets it absorb clinical-trial failures and patent expirations that would sink a single-product biotech, and fund multibillion-dollar acquisitions such as Abiomed, Shockwave Medical, and Intra-Cellular Therapies with cash and investment-grade debt.

Future prospects matter as much as current results. The growth strategies below explain how Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson each plan to expand from here.

Banco Bilbao Vizcaya Argentaria, S.A. growth strategy: After the Banco Sabadell offer lapsed in October 2025, BBVA's growth plan rests on organic lending, digital expansion in Europe and capital returns. Loans and advances to customers grew 11.5 percent in 2025 and customer funds 13.5 percent. The group opened a branch-free digital bank in Italy in October 2021, which passed 800,000 customers by its fourth anniversary and targets one million during 2026, and launched a second digital bank in Germany in June 2025. Capital released by the 2021 transfer of BBVA USA to PNC still underpins buybacks and dividends, with half of 2025 profit earmarked for shareholders.

Johnson & Johnson growth strategy: J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025). Internally it is expanding TREMFYA and CAPLYTA labels, advancing multiple myeloma combinations such as TALVEY plus DARZALEX FASPRO, and developing the OTTAVA soft-tissue surgical robot to compete with Intuitive Surgical's da Vinci.

A closer look at the financial trajectory of Banco Bilbao Vizcaya Argentaria, S.A. and Johnson & Johnson rounds out the comparison.

Banco Bilbao Vizcaya Argentaria, S.A.: BBVA's profit is spread across five business areas. In 2025 Spain contributed ~$4.72B (EUR4.175B) of net attributable profit, Mexico ~$5.95B (EUR5.264B), Turkey ~$910M (EUR805M), South America ~$820M (EUR726M) and Rest of Business ~$709M (EUR627M), while the Corporate Center recorded a ~$1.23B (EUR1.086B) loss. Gross income rose 4.1 percent in reported euros but 16.3 percent at constant exchange rates, the gap being mostly the weaker Mexican peso. Loan-loss impairments were ~$6.86B (EUR6.073B) with a cost of risk of 1.39 percent, and the NPL ratio improved to 2.7 percent with 85 percent coverage. CET1 capital closed at 12.70 percent against a 9.28 percent requirement, and BBVA set total 2025 shareholder distributions at 50 percent of profit, EUR0.92 per share in cash.

Johnson & Johnson: J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.